Scripps Research Logo

News Release

Issued by Garden State Cancer Center at the Center for Molecular Medicine & Immunology

First Immunomedics Science Prize Awarded to Ralph A. Reisfeld of The Scripps Research Institute

Belleville, NJ, and La Jolla, CA. October 21, 1996 -- At the Sixth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, held in Princeton, NJ, from October 10-12, 1996, the first Immunomedics Science Prize was awarded to Dr. Ralph A. Reisfeld for his numerous contributions to the field of monoclonal antibodies and their use in developing targeted therapeutics for cancer.

Dr. Reisfeld, who celebrated his 70th birthday this year, has been in biomedical research for 39 years, and since 1974 has been a Member and Head of the Division of Tumor Cell Biology of The Scripps Research Institute in La Jolla, CA.

In presenting the prize of $5,000 and a plaque, Dr. Gerald L. DeNardo, Director of the Molecular Cancer Institute, University of California-Davis, said on behalf of the awards committee: "Dr. Reisfeld is a pioneer and innovator in the use of reengineered anticancer monoclonal antibodies, and has contributed seminal studies in their application to the treatment of melanoma and neuroblastoma."

Dr. Reisfeld has over 300 publications and has received two 7-year Outstanding Investigator Grants from the National Cancer Institute (NCI), recognizing his research achievements.

The Chairman of the Sixth Conference, Dr. David M. Goldenberg, President of the Garden State Cancer Center in Belleville, NJ, and also a recipient of two 7-year Outstanding Investigator Grants from the NCI, congratulated Dr. Reisfeld in his remarks: "His studies have progressed from developing suitable antibodies, developing appropriate animal models of human malignancy, developing new categories of antibody conjugates, and helping in the design of clinical trials which are now in progress." "He is a true example of a laboratory scientist translating his research to patients," Dr. Goldenberg commented.

The Immunomedics Science Prize was established to recognize scientists who have made significant contributions to improved cancer diagnosis, detection and therapy with targeted cancer agents. The Prize was instituted to mark the U.S. and European approvals of CEA-Scan, the Company's first diagnostic imaging agent for the detection of colorectal cancer.

For further information, please contact Lois Gillespie at (201) 844-7000.

For more information contact:
Office of Communications
10550 North Torrey Pines Road
La Jolla, California 92037